# Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

> **NCT06829563** · PHASE1 · RECRUITING · sponsor: **Rezubio Pharmaceuticals Co., Ltd.** · enrollment: 134 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** RZ-629
- **DRUG:** Placebo
- **OTHER:** Fasted
- **OTHER:** Fed

## Key facts

- **NCT ID:** NCT06829563
- **Lead sponsor:** Rezubio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-02-20
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829563, "Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06829563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*